The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

The issuer is solely responsible for the content of this announcement.

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved 24% weight reduction at 48 weeks in a ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

The United Laboratories International Holdings Limited and Novo Nordisk (NVO) announced earlier that Novo Nordisk and TUL’s wholly-owned ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...